This Policy Statement describes how the offices of Goldman Sachs in the United Kingdom and the European Union (“Goldman Sachs Europe” or “GS Europe”) identify and manage potential conflicts in connection with the publication of research. This Policy Statement summarises more detailed policies issued to relevant Goldman Sachs Europe employees and relevant employees of affiliates involved in the production of research distributed by Goldman Sachs Europe.
This Policy Statement applies to investment research as defined by and produced in accordance with Chapter 12 of the Financial Conduct Authority’s (“FCA”) Conduct of Business Sourcebook (“COBS 12”), and Article 36(1) of Delegated Regulation (EU) 2017/565 (“MiFID II Org Regulation”).
The Goldman Sachs Group, Inc. (together with its affiliates, “Goldman Sachs” or the “firm”) produces independent investment research within its Global Investment Research Division (“GIR”). All such research containing investment recommendations produced by GIR should be regarded as investment research for the purposes of COBS 12.2 and Article 36(1) of MiFID II Org Regulation. Research produced within GIR which does not contain an investment recommendation concerning specific securities, such as reports or sales commentaries produced by sales and trading personnel, should not be regarded as investment research for purposes of this Policy Statement.
Goldman Sachs International, authorised by the PRA and regulated by the FCA and the PRA, disseminates research in the following jurisdictions within the European Economic Area: the Grand Duchy of Luxembourg, Italy, the Kingdom of Belgium, the Kingdom of Denmark, the Kingdom of Norway, the Republic of Finland, and the Republic of Ireland; GSI - Succursale de Paris (Paris branch) which is authorised by the French Autorité de contrôle prudentiel et de resolution (“ACPR”) and regulated by the Autorité de contrôle prudentiel et de resolution and the Autorité des marches financiers (“AMF”) disseminates research in France; GSI - Sucursal en España (Madrid branch) authorized in Spain by the Comisión Nacional del Mercado de Valores disseminates research in the Kingdom of Spain; GSI - Sweden Bankfilial (Stockholm branch) is authorized by the SFSA as a “third country branch” in accordance with Chapter 4, Section 4 of the Swedish Securities and Market Act (Sw. lag (2007:528) om värdepappersmarknaden) disseminates research in the Kingdom of Sweden; Goldman Sachs Bank Europe SE (“GSBE”) is a credit institution incorporated in Germany and, within the Single Supervisory Mechanism, subject to direct prudential supervision by the European Central Bank and in other respects supervised by German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) and Deutsche Bundesbank and disseminates research in the Federal Republic of Germany and those jurisdictions within the European Economic Area where GSI is not authorised to disseminate research and additionally, GSBE, Copenhagen Branch filial af GSBE, Tyskland, supervised by the Danish Financial Authority disseminates research in the Kingdom of Denmark; GSBE - Sucursal en España (Madrid branch) subject (to a limited extent) to local supervision by the Bank of Spain disseminates research in the Kingdom of Spain; GSBE - Succursale Italia (Milan branch) to the relevant applicable extent, subject to local supervision by the Bank of Italy (Banca d’Italia) and the Italian Companies and Exchange Commission (Commissione Nazionale per le Società e la Borsa “Consob”) disseminates research in Italy; GSBE - Succursale de Paris (Paris branch), supervised by the AMF and by the ACPR disseminates research in France; and GSBE - Sweden Bankfilial (Stockholm branch), to a limited extent, subject to local supervision by the Swedish Financial Supervisory Authority (Finansinpektionen) disseminates research in the Kingdom of Sweden.
The firm is subject to a “Global Research Settlement” entered by a United States District Court on October 31, 2003 and modified on March 15, 2010. Whilst not required to do so, the firm has applied the terms of the Global Settlement on a global basis, subject to variations in response to local market practices outside the United States. The Global Research Settlement does not apply to credit research analysts or research analysts in GIR’s Global Macro Research Group.
There are no credit analysts located in Goldman Sachs Europe offices. However, credit research is available to clients globally, and some credit analysts produce research on non-United States issuers. Credit research is produced in accordance with firm policies and procedures designed to satisfy U.S. FINRA Rule 2242.
This Policy Statement is adopted by GSI and GSBE and unless otherwise stated is consistent with the firm’s global policies.
In 2002, GIR adopted the principles set out below:
As reflected above in the Statement of our Investment Research Principles the firm identifies and manages potential conflicts arising from the publication of research. These conflicts can arise with regard to corporate clients, investor clients, the proprietary and agency trading activities of the firm, the firm’s investment banking activities and the interests of the firm’s officers and employees. The policies summarised in sections (C) through (L) describe the way in which the firm seeks to manage these conflicts.
In 2002, GIR became a separate division of the firm, reporting to the firm’s Executive Office. GIR Senior Managers (SMF) have responsibility for the management and oversight of the activities of the GIR division conducted through GSI. The GIR SMFs report ultimately to the head of GSI based in London and the firm’s Global Head of GIR based in New York.
A member of GSBE’s Executive Board has been appointed as responsible for GIR’s activities within GSBE, and GIR has appointed a Head of GIR GSBE who has supervisory oversight of GIR’s activities within GSBE. The Head of GIR GSBE also has a functional reporting line into the GIR Senior Managers.
Analysts are not supervised by, and do not report to, investment banking personnel or personnel who directly supervise day-to-day sales and trading activities.
The firm has 1) established controls designed to manage any receipt by research analysts of non-public or proprietary information from other areas of the firm, and 2) implemented procedures to prevent analysts’ independence from being compromised by any interactions that they might have with the firm’s investment bankers or Global Markets personnel.
The firm has adopted policies and procedures and conducted training of analysts, such that they may receive material non-public information only in accordance with clear wall-crossing procedures. These procedures include obtaining appropriate approvals of research management and compliance, logging and reviewing such approvals and imposing appropriate restrictions on the permitted activities of analysts concerned while the information remains non-public.
Analysts are required to certify in each research report that i) the views expressed in the report accurately reflect their personal views about the subject company or companies and its or their securities, and ii) no part of the analyst’s remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.
Analysts interact with investing clients, providing them with informed and impartial research opinions. Analysts participate in and facilitate a continuing dialogue between investors and corporate issuers. Analysts frequently discuss their opinions with the firm’s sales and trading personnel.
Analysts are not permitted to participate in sales pitches for investment banking mandates and are not permitted to make presentations or actively participate in road shows relating to an investment banking transaction.
Analysts are permitted to perform certain other roles where the firm believes that it would not compromise their independence or the appearance thereof, including:
GIR analysts’ remuneration is determined exclusively by GIR management in conjunction with firm management. Investment banking personnel may not have any input into such decisions. Investment banking personnel are not permitted to perform or contribute to annual appraisals of analysts.
Analysts’ remuneration is not directly linked to specific investment banking or global markets transactions, but may be related to the firm’s overall performance which includes investment banking and global markets results.
In GIR under the Global Research Settlement, a significant portion of an equity analyst’s compensation is based on the quality and accuracy of the analyst’s research. GIR management employs a series of metrics and surveys in such determination.
The following are factors which must, if applicable, be taken into account by GIR management when determining an equity lead analyst’s1 remuneration:
The following are factors which may be taken into account by GIR management when determining an equity lead analyst’s remuneration:
Analysts are not permitted to accept any remuneration or other benefit from an issuer or any other party with a material interest in the subject-matter of the research in respect of the publication of research.
Analysts are not permitted to accept any inducement for the production of favourable research.
These restrictions do not preclude the acceptance of reasonable corporate hospitality in accordance with the firm’s general policies regarding gifts and entertainment.
Analysts are prohibited from trading or owning publicly available securities or ‘related financial instruments’ issued by companies in their business unit or industry area of coverage.
Prior approval is required for investments in private companies or private funds and also for any outside business activities such as directorships, or earned income from a source other than their employment at the firm. An analyst may not perform services for remuneration fora company covered by such analyst either on behalf of the firm or in a personal capacity. Analysts cannot invest in private companies in their industry area of coverage.
All GIR employees must obtain pre-approval to buy or sell any publicly available equity securities and equity linked securities, including convertibles and derivatives; bonds; closed-end mutual funds; and any other comparable investment vehicle.
Analysts (and household members of analysts) may not serve as an officer, director, employee or advisor to a company in the analyst’s coverage area.
In accordance with GIR policy, analysts are permitted to prepare a separate schedule of facts from the unpublished report for fact-checking with subject companies. Equity and credit analysts may not provide a subject company with a written draft summary. This policy does not apply to pre-deal research (see further Section L below).
Final decisions on coverage are independently made by GIR management. In making such decisions GIR management may consider input from various sources to the extent permitted by the Global Research Settlement or FINRA Rules 2241 and 2242 or Article 37 of the MiFID Org Regulation or SYSC 10 as applicable, including investors, managers of the firm’s Global Markets Division and Investment Banking Division.
In general, the policy of GIR management is to cover companies where the firm has had a lead role in the companies’ offering of securities.
GIR’s policy is to ensure that statements by analysts that are new and material achieve broad, global dissemination both to clients and sales/trading personnel.
The decision to terminate coverage of an issuer must be approved by GIR management. The firm publishes a final note stating that coverage has been terminated.
Where the firm is acting in an advisory capacity in a publicly announced merger or strategic transaction involving a company, in addition to compliance with any applicable rules or regulations (e.g., the UK City Code on Takeovers and Mergers), if the EMEA Equity Research Investment Review Committee views the proposed merger or strategic transaction as material to the analysis of the security such that the analyst cannot responsibly analyse the rating and price target for the security and/or subject to major contingencies that the market will view as critical, the investment rating and target price, if any, will be suspended temporarily and the security shown as “not rated”.
The full list of GIR disclosures can be viewed at: http://www.gs.com/research/hedge.html
In accordance with common practice in certain markets in Europe and consistent with legal advice, GIR produces, from time to time, research (commonly termed “pre-deal” research) prior to an offering of securities where GSI or GSBE also have an investment banking mandate in respect of the offering. In connection with producing pre-deal research GS Europe has adopted procedures designed to:
Our weekly newsletter with insights and intelligence from across the firm
By submitting this information, you agree to receive marketing emails from Goldman Sachs and accept our privacy policy. You can opt-out at any time.